Recent Updates
Recently added Catalysts
LXEO Positive Sentiment Score: 75/100

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tuesday, January 7, 2025 1 min read
Key Takeaway: Lexeo Therapeutics, a clinical stage genetic medicine company, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. CEO R. Nolan Townsend will deliver the presentation in San Francisco, California. The company focuses on innovative treatments for genetically defined cardiovascular diseases and related conditions. A live webcast of the event will be available, with a replay following the presentation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexeo Therapeutics is set to present at a well-regarded industry conference.
  • The company is focused on pioneering treatments for significant health issues.
  • Live webcasting allows for broad accessibility to their presentation.

Full Press Release Details

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.
The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
ctanzi@kendallir.com

Frequently Asked Questions

When will Lexeo Therapeutics present at the J.P. Morgan Conference?

Lexeo Therapeutics will present on January 15, 2025, at 8:15 AM PT.

Where can I watch the Lexeo Therapeutics presentation?

The presentation will be webcast live on the Company's website under News & Events.

What is the focus of Lexeo Therapeutics?

Lexeo Therapeutics focuses on treatments for genetically defined cardiovascular diseases.

What diseases does Lexeo target in its pipeline?

Lexeo targets genetically defined cardiovascular diseases and APOE4-associated Alzheimer's.

What approach does Lexeo use in its development process?

Lexeo employs a stepwise development approach using early proof-of-concept data.

Tags: LXEO Viatris Investor Conferences Healthcare Lexeo Therapeutics cardiovascular diseases J.P. Morgan Healthcare Conference APOE4 genetic medicine
Last updated: Jan 7, 2025